The European Medicines Agency has granted Orphan Drug Designation to Aridis Pharmaceuticals’ (NASDAQ:ARDS) AR-501, an inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.
Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.